BioAge Labs' NLRP3 inhibitor shows strong inflammation reduction in obesity with elevated systemic inflammation

California-based BioAge Labs [reported Phase I results](https://www.globenewswire.com/news-release/2026/04/21/3277765/0/en/BioAge-Reports-Positive-Phase-1-Data-for-BGE-102-a-Novel-Oral-NLRP3-Inhibitor-Demonstrating-Potential-Best-in-Class-Reductions-in-hsCRP.html) for BGE-102, an oral small-molecule NLRP3 inhibitor, in participants with obesity and elevated systemic inflammation, with the company saying both 60 mg and 120 mg once-daily doses produced median hsCRP reductions of 85% or greater across the dosing period. In the two obese multiple ascending dose cohorts — 120 mg once daily for 14 days (n=14 active) and 60 mg once daily for 21 days (n=15 active) — BGE-102 produced rapid reductions in hsCRP from Day 7 that were sustained through end of dosing. The 60 mg cohort achieved median hsCRP reductions of 85% at Day 7, 80% at Day 14, and 86% at Day 21, with 87% of participants on active treatment (13/15) reaching normalized hsCRP below 2 mg/L and 60% (9/15) reaching 1 mg/L or below. The 120 mg cohort showed 83% reduction at Day 7 and 86% at Day 14, with 93% (13/14) achieving hsCRP below 2 mg/L and 71% (10/14) reaching 1 mg/L or below. IL-6 reductions were consistent across both doses — 78% and 69% respectively at Day 7 — and fibrinogen fell by approximately 20–30% at both dose levels across measured timepoints. All treatment-emergent adverse events were mild to moderate and self-limited, with no serious adverse events, no discontinuations, and no clinically meaningful changes in vital signs, ECGs, or laboratory values. The BGE-102 Phase I SAD/MAD trial was reportedly a randomized, double-blind, placebo-controlled study enrolling healthy volunteers and participants with obesity (BMI 32–42) with hsCRP above 3 mg/L at baseline. The data reported here cover only the two obese MAD cohorts; results from single ascending dose and healthy volunteer MAD cohorts, including pharmacokinetics, brain penetration, and IL-1β suppression, were disclosed previously. The primary endpoints were pharmacokinetics and safety; hsCRP, IL-6, and fibrinogen were exploratory pharmacodynamic endpoints, and no formal efficacy conclusions can be drawn from a Phase I pharmacodynamic dataset of this size. No NCT code was provided for the trial. BGE-102 is an orally available, brain-penetrant small molecule that inhibits the NLRP3 inflammasome, a multiprotein complex implicated in chronic inflammation across cardiovascular, metabolic, and neurodegenerative settings. The NLRP3 inhibitor class is drawing attention from multiple developers, including Novartis, whose oral NLRP3 inhibitor [iptacopan](https://app.allsci.com/clinical-trial/ASC-CT-0000000033424-1.0-1745700230) is in later-stage development for complement-mediated diseases, and Novo Nordisk, [which acquired Cardior Pharmaceuticals](https://cardior.de/wp-content/uploads/2024/03/PR240325_Cardior_Final.pdf) partly for inflammation-related assets. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/bge-102-inflammation-obesity-bioage-labs-shows)